AH-Plus Epoxy Resin Sealer
Small molecule
AH-Plus Epoxy Resin Sealer is one of 31 small molecule programs targeting Pulpitis. It is currently in development.
1
Indications
2
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Pulpitis
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Decadron
QQuince Therapeutics S.p.A.
Approved
Tylenol
KKenvue Brands
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Medrol
PfizerPhase 3
Advil
KKenvue Brands
Phase 3
Adrenaline
SSamson Clinical Operations Pty Ltd
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Healing1 trial
Periapical Healing in Response to Endodontically Treated Teeth With Different Sealing Cement
Active, not recruiting·IInstitucion Universitaria Colegios de Colombia·Phase 4·NCT06482593·72 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AH-Plus Epoxy Resin Sealer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- JJaweria Gul Keyani